ENding HIV Transmission to Infants by Generating Evidence to Optimize Prevention and Care for Pregnant and Postpartum Adolescent Girls and Young Women With HIV in Tanzania (ENGAGE)
Led by Karolinska Institutet · Updated on 2025-06-29
222
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Similar Trials
Frequently Asked Questions
Research Publications
Sponsors
K
Karolinska Institutet
Lead Sponsor
M
Management and Development for Health, Tanzania
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating better ways to care for pregnant and postpartum adolescent girls and young women (AGYW) aged 15-24 years with HIV in Tanzania. The study aims to understand how often these young women attend health appointments and stay on treatment up to two years after giving birth, how many babies remain HIV-free for two years, factors influencing repeat pregnancies, and the best ways to support health care engagement. The project focuses on improving prevention of HIV transmission to infants and optimizing HIV treatment outcomes for this vulnerable group.
The study involves analyzing health service records from 559 facilities in Tanzania for all AGYW who started prevention of mother-to-child transmission (PMTCT) services between 2018 and 2020. It includes qualitative interviews to gather experiences, co-creation of an intervention package with participants and healthcare providers, and a cluster-randomized trial to test this intervention. The intervention package may include peer mentor support, male partner involvement, flexible clinic hours, and phone reminders, aiming to improve care engagement and retention.
Participants will provide health data through existing records and take part in interviews and workshops. The trial will follow pregnant AGYW receiving PMTCT services between January and June 2026, with outcomes measured up to two years after delivery. Researchers will assess time to treatment dropout, viral load detectability, infant HIV-free survival, repeat pregnancies, and use of prevention services. The study includes ongoing monitoring of intervention quality and ethics oversight, with participation lasting until June 2027.
CONDITIONS
Brief Title
Optimizing Prevention and Care for Pregnant and Postpartum Adolescent Girls and Young Women With HIV in Tanzania
Who Can Participate
Age: 15Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Female adolescent girls and young women (AGYW) aged 15 to 24 years living with HIV
Pregnant or postpartum AGYW who started PMTCT services between January 1, 2018, and December 31, 2020
Infants born to the included AGYW during the study period
AGYW living with HIV currently pregnant, previously pregnant/postpartum, or never pregnant (for qualitative studies)
Health care providers, spouses/partners, parents, and community stakeholders involved in PMTCT services
Pregnant AGYW living with HIV receiving vertical HIV prevention services between January 1, 2026, and June 30, 2026, with follow-up until June 30, 2027
Participants involved in earlier qualitative studies and research team members (for co-production phase)
You will not qualify if you...
AGYW whose antiretroviral therapy (ART) status is not recorded
Women who have not started ART treatment
Mentally or severely ill individuals unable to participate in study activities
AGYW whose ART status is not recorded (for cluster-randomized trial phase)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 6 months (January 1, 2026 to June 30, 2026)
Participants receive a co-produced package of interventions integrated into routine PMTCT care to improve engagement, retention, and health outcomes. The intervention includes approaches such as peer mentor mothers, male partner involvement, flexible clinic hours, and mobile phone reminders. A focal team at each facility supports delivery and monitors intervention quality.
Weekly visits in the first month and monthly visits thereafter
Follow-up
Duration - 12 months (July 1, 2026 to June 30, 2027)
Participants are followed for at least one year after the intervention period to monitor ART retention, viral load, HIV-free survival of infants, and other health outcomes using routine healthcare data and additional interviews.
Vertical HIV transmission within 18 months post partum among women on lifelong antiretroviral therapy for HIV in Dar es Salaam, Tanzania: a prospective cohort study.